tirzepatide

dual-agonist · glp-1 / gip

Dual GLP-1 / GIP receptor agonist — currently the most clinically characterized metabolic peptide on the market.

vial size

for laboratory use only — not for human consumption. ships from tallinn within 24 h, EU delivery in 48 h.

research monograph

what the literature shows.

A condensed monograph drawn from preclinical and clinical literature. Cited mechanisms, specifications and the research case for tirzepatide.

01 · mechanism of action

Tirzepatide is a dual GLP-1 / GIP receptor agonist developed by Eli Lilly that showed extraordinary metabolic effects in preclinical and clinical studies. In animal studies on obese mice and rats it produced weight reductions of 25–40 % of baseline weight — significantly stronger than pure GLP-1 agonists. The GIP component enhances glucose-dependent insulin secretion and improves insulin sensitivity through direct action on adipocytes. SURPASS clinical studies (2021–2023) in type-2 diabetics achieved mean weight reductions up to 22 % and HbA1c reductions of 2.5 percentage points. In NASH animal models tirzepatide significantly reduced liver fat content, inflammatory markers and fibrotic changes.

02 · product specifications

Each vial contains 15 mg tirzepatide as lyophilized powder at ≥ 99.3 % purity (HPLC). Suitable for receptor binding studies, insulin secretion tests in pancreatic cell models and metabolomic investigations of the GLP-1 / GIP axis.

03 · research advantages

FDA-approved as Mounjaro and currently the most studied metabolic peptide with extensive clinical data. Dual receptor activation surpasses the effect of semaglutide in both animal studies and clinical settings, making it a leading research molecule in obesity and diabetes research.

datasheet

full specification.

Identity, mass, purity reference and storage profile for the current lot of tirzepatide. For laboratory use only.

catalog no.: PH-1015-T
cas: 2023788-19-2
molecular weight: 4813.45 g/mol
purity (hplc): ≥ 99.3 % (hplc)
endotoxin: < 0.5 eu/mg
sequence: 39-residue analogue (lilly LY3298176)
residues: 39 aa
appearance: white lyophilized powder
reconstitution: bacteriostatic water · 0.9 % nacl
stability (reconstituted): 28 d at 2–8 °c
shelf life (lyophilized): 24 m at −20 °c
storage: −20 °c, protect from light
current lot: trz-260318
current exp.: 09 / 2027
lead time: ships in 24 h

same series · metabolic

from the same bench.

full catalog

back to catalog